Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amneal Pharmaceuticals reports strong Q4 earnings and outlines growth strategies

Amneal Pharmaceuticals delivered strong Q4 2022 results with revenue of $610 million and adjusted EBITDA of $154 million, expecting stable performance in 2023 with total revenue of $2.25-2.35 billion.
The company's strategic focus on complex, high-growth products, international expansion, and new product launches positions it for growth opportunities despite challenges in generic growth rates and competitive pressures.
With a robust biosimilars growth plan, unique pricing strategies, and market expansion initiatives, Amneal Pharmaceuticals aims to capture market share, drive revenue growth, and sustain its performance in the pharmaceutical industry.
Despite facing challenges such as potential competition and manufacturing delays, Amneal Pharmaceuticals remains optimistic about its growth prospects, emphasizing long-term strategies for revenue expansion and market positioning.

Amneal Pharmaceuticals reports strong Q1 results and eyes strategic growth

Amneal Pharmaceuticals' Q1 2023 performance reflects strategic growth initiatives across all segments, positioning the company for future success.
While challenges like debt reduction and refinancing exist, the company's strengths in product diversification and market adoption offer growth potential.
Opportunities in Injectables, Biosimilars, and capital allocation strategies provide avenues for revenue growth and operational excellence.

Amneal Pharmaceuticals reports strong Q2 earnings, eyes sustainable growth

Amneal Pharmaceuticals is on track for sustainable growth and EBITDA acceleration.
The company is well-positioned to capitalize on the growth potential in biosimilars and complex generics.
With a focus on organic growth and new product launches, Amneal aims to drive revenue and expand market share.

Amneal Pharmaceuticals excels in Q3, eyes international expansion and specialty growth

Amneal Pharmaceuticals reported strong financials, raised guidance, and highlighted growth in key segments. The company's strategic focus on operational efficiency, supply chain expansion, and international growth positions it for sustained success. Challenges include managing expenses and liabilities, but opportunities in new markets and product segments offer avenues for growth.

Amneal Pharmaceuticals posts record revenue in Q4 2023, eyes biosimilar growth

Amneal Pharmaceuticals reported robust financials for Q4 2023 and full-year 2023, with record revenue and EBITDA figures. The company's strategic focus on biosimilars, portfolio expansion, and growth initiatives underpin its optimistic outlook for 2024. Despite industry challenges, Amneal remains committed to innovation, affordability, and addressing pricing issues.

Amneal Pharmaceuticals reports record Q1 revenues and eyes biosimilar growth

Amneal Pharmaceuticals' Q1 performance reflects robust growth across all segments, underpinned by strong financial execution and a sustainable growth profile.
The company's strengths lie in its market position, diverse portfolio, commitment to quality, and strategic partnerships, positioning them for continued success.
While facing challenges related to product approvals and revenue uncertainties, Amneal is well-positioned to capitalize on opportunities in biosimilars, strategic partnerships, and market expansion.

Amneal Pharmaceuticals excels in Q2, eyes international expansion for growth

Amneal Pharmaceuticals delivered a strong performance in Q2 2024, with robust revenue growth and raised guidance, signaling confidence in future prospects.
The company's strategic strengths lie in international expansion, diversified revenue streams, and a focus on financial stability through debt reduction and investments.
Challenges include maintaining growth momentum, effective execution of expansion plans, and balancing debt reduction with growth investments.
Opportunities abound in new product approvals, market expansion, and innovation, positioning Amneal Pharmaceuticals for sustained growth and market leadership.

Amneal Pharmaceuticals reports robust Q3 results and eyes future growth

Amneal Pharmaceuticals' Q3 performance reflects strong revenue growth and strategic product initiatives in key therapeutic areas.
The company's focus on affordable medicines, biosimilars, and strategic investments underscores its commitment to future growth.
While facing challenges in market competition and operational optimization, Amneal is well-positioned to leverage growth opportunities.
With a solid financial performance and a focus on sustainable value creation, Amneal is poised for long-term success in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the below investor conferences. Jefferies 14th Annual Global Healthcare Conference November 14, 2023 London, UK Presentation – 8:30 AM GMT Piper Sandler 35th Annual Healthcare Conference November 28, 2023 New York, New York Presentation – 9:00 AM EST A live webcast of the prese.

Amneal to Participate at Upcoming Investor Conferences

Amneal (AMRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Amneal (AMRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Amneal (AMRX) Upgraded to Buy: Here's Why

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results for the third quarter ended September 30, 2023. The Company also raised its financial guidance for the year ending December 31, 2023, which was most recently issued on August 4, 2023. The Company plans to report actual third quarter 2023 financial results on November 7, 2023. Unaudited Preliminary Financial Results for the Thir.

Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance

Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the addition of two denosumab biosimilars referencing both Prolia® and XGEVA® to its biosimilar pipeline. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various forms of cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. The two denosuma.

Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio

Amneal (AMRX) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Amneal (AMRX)

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Third Quarter 2023 Results on November 7, 2023.

Amneal to Report Third Quarter 2023 Results on November 7, 2023

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for calcium gluconate in sodium chloride injection, 1000 mg/50 mL and 2000 mg/100 mL. This injectable product is currently on the U.S. FDA shortage product list. The product approval received the FDA's Competitive Generic Therapy (“CGT”) designation with 180-.

Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received its first product approval in China. Sevelamer carbonate was approved and is expected to launch shortly. In addition, the Company expects to launch oseltamivir phosphate in China this year as well, upon approval. In total, Amneal has 6 products pending review in China with more product registrations planned over time. Since 2019, the Company has collaborated.

Amneal Receives First Product Approval in China

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for lisdexamfetamine dimesylate capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. Lisdexamfetamine dimesylate capsules is a generic version of Vyvanse®. This ADHD product is currently on the U.S. FDA shortage product list, and Amneal has already begun sup.

Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023 in Boston. Mr. Patel will also be hosting a fireside chat at 8:00 AM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at https://inv.

Amneal to Participate at the 2023 Wells Fargo Healthcare Conference

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study assessing the efficacy and safety of IPX203 versus optimized immediate-release carbidopa/levodopa (IR CD/LD) for the treatment of Parkinson's disease (PD). The study met its primary and secondary endpoints finding that IPX203 provided more hours of “Good On” time per day, less “Off” time per day, and more “Good On” time per dose.

JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Ginkgo Bioworks Holdings

FuboTV

Modular Medical

Are you on the hunt for the most promising penny stocks to invest in for 2023? Join the ever-expanding group of investors who are keen to leverage the booming market.

Penny Stocks To Buy? 4 To Watch With Big News This Month

Diversified Healthcare Trust

Gracell Biotechnologies

Protalix Biotherapeutics

Tonix Pharmaceuticals Hld

Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It's no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation and thereby increasing market volatility.

Penny Stocks To Buy? 5 To Watch With Big News This Week

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q2 2023 Earnings Conference Call August 4, 2023 8:30 AM ET Company Participants Anthony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder and Co- Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Harsher Singh - Head, Biosciences Conference Call Participants Nathan Rich - Goldman Sachs Les Sulewski - Truist David Amsellem - Piper Sandler Operator Hello, everyone and welcome to the Amneal Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Bruno, and I'll be operating your call today.

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2023 Earnings Call Transcript

The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amneal (AMRX) Reports Q2 Earnings: What Key Metrics Have to Say

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.19 per share a year ago.

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2023. “We are pleased to raise our full year 2023 guidance following another strong quarter. Our momentum in the first half of the year underscores the solid execution of our strategy and ability to drive continued growth across our diversified portfolio. We expect many key catalysts ahead, including complex generics launches.

Amneal Reports Second Quarter 2023 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Administration (FDA) for three key complex generic products, including:     Product Dosage Category U.S. IQVIA sales (TTM May 2023) 1   Albuterol sulfate inhalation Inhalation $814 million 2   Bimatoprost ophthalmic solution, 0.01% Ophthalmic $779 million 3   Propofol emulsion Injectable $3.

Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE: AMRX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX

A Complete Response Letter from the FDA temporarily tanked AMRX stock. New launches and established products should contribute to Amneal Pharmaceuticals' Q2 growth. A generic to blockbuster sets Amneal up nicely for Q3 and onward.

Amneal Pharmaceuticals Could Have An Upbeat Q2

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2023 financial results on Friday August 4, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 4, 2023. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

Amneal to Report Second Quarter 2023 Results on August 4, 2023

Amneal has more than 270 products. On Tuesday, the company launched a generic for Xyrem to treat excessive daytime sleepiness.

News for Amneal Pharmaceuticals Stock (AMRX)